D
Daniel Homerick
Researcher at University of California, Davis
Publications - 6
Citations - 897
Daniel Homerick is an academic researcher from University of California, Davis. The author has contributed to research in topics: Cytotoxic T cell & IL-2 receptor. The author has an hindex of 5, co-authored 6 publications receiving 832 citations. Previous affiliations of Daniel Homerick include Walter and Eliza Hall Institute of Medical Research.
Papers
More filters
Journal ArticleDOI
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases
Christine Beeton,Heike Wulff,Nathan Standifer,Philippe Azam,Katherine M. Mullen,Michael W. Pennington,Aaron Kolski-Andreaco,Eric Wei,Alexandra Grino,Debra Counts,Ping H. Wang,Christine J. LeeHealey,Brian S. Andrews,Ananthakrishnan Sankaranarayanan,Daniel Homerick,Werner W. Roeck,Jamshid Tehranzadeh,Kimber L. Stanhope,Pavel I. Zimin,Peter J. Havel,Stephen M Griffey,Hans Guenther Knaus,Gerald T. Nepom,George A. Gutman,Peter A. Calabresi,K. George Chandy +25 more
TL;DR: It is demonstrated that disease-associated autoreactive T cells from patients with type-1 diabetes mellitus or rheumatoid arthritis are mainly CD4+CCR7−CD45RA− effector memory T cells (TEM cells) with elevated Kv1.3 potassium channel expression, which ameliorate pristane-induced arthritis in rats and reduce the incidence of experimental autoimmune diabetes in diabetes-prone rats.
Journal ArticleDOI
Design of PAP-1, a Selective Small Molecule Kv1.3 Blocker, for the Suppression of Effector Memory T Cells in Autoimmune Diseases
Alexander Schmitz,Ananthakrishnan Sankaranarayanan,Philippe Azam,Kristina Schmidt-Lassen,Daniel Homerick,Wolfram Hänsel,Heike Wulff +6 more
TL;DR: A series of new phenoxyalkoxypsoralens that exhibit 2- to 50-fold selectivity for Kv1.3 as a target for immunosuppression and could potentially be developed into orally available immunomodulators are identified.
Journal ArticleDOI
Targeting Effector Memory T Cells with the Small Molecule Kv1.3 Blocker PAP-1 Suppresses Allergic Contact Dermatitis
Philippe Azam,Ananthakrishnan Sankaranarayanan,Daniel Homerick,Stephen M Griffey,Heike Wulff +4 more
TL;DR: It is proposed that PAP-1, a small molecule Kv1.3 blocker, could potentially be developed into a drug for the topical treatment of inflammatory skin diseases such as psoriasis.
Journal ArticleDOI
Pharmacological Profiling of Orthochirus scrobiculosus Toxin 1 Analogs with a Trimmed N-Terminal Domain
Stéphanie Mouhat,Georgeta Teodorescu,Daniel Homerick,Violeta Visan,Heike Wulff,Yingliang Wu,Stephan Grissmer,Hervé Darbon,Michel De Waard,Michel De Waard,Jean-Marc Sabatier +10 more
TL;DR: It is demonstrated that progressive trimming of the N-terminal domain of [Lys16,Asp20]-OSK1 results in marked changes in its pharmacological profile, in terms of both K+ channel affinity and selectivity.
Journal ArticleDOI
A New Class of Blockers of the Voltage-Gated Potassium Channel Kv1.3 via Modification of the 4- or 7-Position of Khellinone
TL;DR: Multiple parallel synthesis of a new class of khellinone derivatives selectively alkylated at either the 4- or 7-position via the phenolic OH are described and it is shown that several chloro, bromo, methoxy, and nitro substituted benzyl derivatives inhibit Kv1.3 with submicromolar potencies.